[Efficacy and safety of venetoclax and azacitidine in the treatment of refractory and relapsed acute myeloid leukemia]

Zhonghua Xue Ye Xue Za Zhi. 2021 Oct 14;42(10):861-864. doi: 10.3760/cma.j.issn.0253-2727.2021.10.012.

[Article in Chinese]

Authors

L H Zong¹, X X Wu¹, J Zhang¹, M Y Li¹, B Q Song¹, J Y Kong¹, X Kong¹, X H Hu¹, X B Bao¹, H Y Qiu¹, D P Wu¹

Affiliation

¹ The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, Suzhou 215006.

PMID: 34788928
PMCID: PMC8607025
DOI: 10.3760/cma.j.issn.0253-2727.2021.10.012

No abstract available

MeSH terms

Antineoplastic Combined Chemotherapy Protocols
Azacitidine* / therapeutic use
Bridged Bicyclo Compounds, Heterocyclic / therapeutic use
Humans
Leukemia, Myeloid, Acute* / drug therapy
Sulfonamides / therapeutic use

Substances

Bridged Bicyclo Compounds, Heterocyclic
Sulfonamides
Azacitidine
venetoclax

Grants and funding

基金项目：江苏省自然科学基金面上项目（BK20201168）